Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIMIGA Study in Primary IgA Nephropathy
NCT07750249Phase 1Enrolling by invitation
- Sponsor
- University Hospital Martin
- Start
- Mar 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sodium butyrate in IgA nephropathy (IgAN) (2 arms), sponsored by University Hospital Martin. Primary endpoint: Reduction of Proteinuria (Urinary Protein-Creatinine Ratio) at 24 weeks. Started Mar 2025; status: enrolling by invitation.
02
Drugs
sodium butyrate
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07750249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07750249.